Soleno Therapeutics, Inc. (SLNO) Research

Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.

Market snapshot

Symbol
SLNO
Price
$53.01
Day change
0.00%
Market cap
$2.8B
P/E ratio
28.75x
52-week range
29.43-90.3199
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$80.00

Peer companies

  • Ascentage Pharma Group International (AAPG)
  • Apogee Therapeutics, Inc. (APGE)
  • Celcuity Inc. (CELC)
  • Centessa Pharmaceuticals plc (CNTA)
  • Dyne Therapeutics, Inc. (DYN)
  • Mirum Pharmaceuticals, Inc. (MIRM)
  • Praxis Precision Medicines, Inc. (PRAX)
  • Ultragenyx Pharmaceutical Inc. (RARE)

Recent insider activity

  • Yen Kristen — D-Return (37639 shares) on 2026-05-18
  • Yen Kristen — D-Return (1741 shares) on 2026-05-18
  • Yen Kristen — D-Return (4999 shares) on 2026-05-18
  • Yen Kristen — D-Return (4000 shares) on 2026-05-18
  • Yen Kristen — D-Return (666 shares) on 2026-05-18

Open Soleno Therapeutics, Inc. (SLNO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.